Astrazeneca’s Bi-specific Antibody, Rilvegostomig, Derived From Compugen’s Com902, Is Expected To Progress Into Phase 3 This Year
AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific antibody, and is also developing an expanded Phase 2 program. COM902, Compugen's
US Stocks On Recovery Course As Earnings Lend Support: Fed’s Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst
The see-sawing mood in the market continues as Fed’s data dependency creates volatility. The index futures point to a solidly higher opening on Thursday, signaling a reversal in the sentiment seen in the previous session.
Cues From Wednesday’s Trading:
Earnings Scheduled For February 9, 2023
Companies Reporting Before The Bell
• AstraZeneca (NASDAQ:AZN) is expected to report quarterly earnings at $0.67 per share on revenue of $11.21 billion.
AstraZeneca Expects FY23 Revenues To Increase By Low-To-Mid Single-Digit Percentage, With Core EPS To Increase By High Single-Digit To Low Double-Digit Percentage
Total Revenue excluding COVID-19 medicines is expected to increase by a low double-digit percentage
AstraZeneca Q4 EPS $0.69 Beats $0.67 Estimate, Sales $11.21B Miss $11.21B Estimate
AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.67 by 2.99 percent. This is a 17.86 percent decrease over earnings of $0.84 per share from the same
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Johnson & Johnson’s Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Cantor Fitzgerald is previewing its thoughts on a potential interim analysis for Johnson & Johnson’s (NYSE:JNJ) Phase 3 MARIPOSA study of Rybrevant (amivantamab)…
